Nabumetone dry suspension

This product is a non-acidic non-steroidal anti-inflammatory drug and a prodrug. It is rapidly metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA) in the liver and has antipyretic, analgesic and anti-inflammatory effects. The anti-inflammatory, analgesic and antipyretic effects of this product are related to the fact that the active metabolites of nabumetone inhibit the synthesis of prostaglandins in inflammatory tissues. This product has little effect on the gastric mucosa: this product is a non-acidic, non-ionic prodrug, and has no obvious local direct effect on the gastric mucosa during the absorption process; at the same time, this product has little inhibitory effect on the physiological cyclooxygenase of the gastric mucosa. Therefore, the incidence of gastrointestinal mucosal erosion and bleeding caused by this product is low. This product has no effect on bleeding and coagulation: this product has no effect on the platelet aggregation induced in vitro in blood samples of healthy volunteers.

Nabumetone.

This product is white granular powder.

1. Various acute and chronic inflammatory arthritis; 2. Soft tissue rheumatism; 3. Sports soft tissue injuries, sprains and contusions, etc.; 4. Others such as surgical pain, post-traumatic pain, toothache, pain after tooth extraction, dysmenorrhea, etc.

Common adult dosage: Take with water, 1.0 g (2 bags) at a time, take with 150 ml warm water, once a day, before going to bed. For severe or persistent symptoms, or acute exacerbation, an additional 0.5-1 g (1-2 bags) can be added, and the dose should be taken in the early morning. Adults weighing less than 50 kg can start with 0.5 g (1 bag) per day and gradually increase to the effective dose.

⑴ Gastrointestinal tract: nausea, vomiting, indigestion, diarrhea, abdominal pain and constipation, about 1% to 3%. Upper gastrointestinal bleeding, about 0.7%. In the cases of this product, the incidence of ulcers in the short-term treatment (6 weeks to 6 months) group and the long-term treatment (8 years) group were 0.1% and 0.95%, respectively. The incidence of diarrhea increased with daily administration of 2g of nabumetone. ⑵ Nervous system: manifestations include headache, dizziness, tinnitus, sweating, insomnia, drowsiness, tension and dreaminess, with an incidence of less than 1.5%. ⑶ Skin: rash and itching, about 2.1%, edema, about 1.1%. ⑷ Rare or occasional adverse reactions include jaundice, abnormal liver function, anxiety, depression, paresthesia, tremor, dizziness, bullous rash, urticaria, dyspnea, asthma, allergic pneumonia, proteinuria, hematuria and angioneurotic edema.

It is contraindicated for patients with active gastrointestinal ulcers or bleeding, severe liver function abnormalities, or allergies to this product and other non-steroidal anti-inflammatory drugs.

Precautions for children: The safety and efficacy of nabumetone in pediatric patients have not been determined, so this product is not recommended for children. Precautions for pregnancy and lactation: Pregnant women are not recommended to use this product in the last 3 months of pregnancy and during lactation. Precautions for the elderly: There is no significant difference in the efficacy and safety of nabumetone between the elderly over 65 years old and the young. However, like other non-steroidal anti-inflammatory analgesics and antipyretics, elderly patients should maintain the lowest effective dose when using this product.

(1) The absorption rate of this product is not affected by the combined use of aluminum hydroxide gel, aspirin or acetaminophen. However, it is generally not recommended to use two or more non-steroidal anti-inflammatory drugs at the same time. (2) There is no interaction between this product and warfarin in healthy volunteers. However, there is no data on the combined use of these two drugs in patients. (3) The dose should be appropriately reduced when this product is used in combination with acetyl anticonvulsants and sulfonylurea hypoglycemic drugs.

Light-proof and sealed.

0.5g

24 months

Nantong Jiuhe Pharmaceutical Co., Ltd.

• Founded in:

  2002-07-29

• Address:

  No. 118, Jianghai West Road, Chengao Industrial Park, Rudong, Jiangsu Province

• Tax NO.:

  91320623741329559W

• Registered Funds:

  10.18 million yuan

• Website:

  Log in to view

• Email:

  Log in to view